Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)

Organon

Status: Completed

Conditions: Allergic Rhinitis

Treatments: Drug: mometasone furoate

Study type: Observational

Funder types: Industry

Identifiers

NCT00903721

P05876

Details and patient eligibility

About

The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Enrollment: 3,806 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis.

Exclusion criteria

• Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection [symptoms may exacerbate]
• Patients with a history of hypersensitivity to any ingredient of this drug

Trial design

3,806 participants in 2 patient groups

1

Description:

Patients with perennial allergic rhinitis

Treatment:

Drug: mometasone furoate

2

Description:

Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis)

Treatment:

Drug: mometasone furoate